Study of PCS6422 with capecitabine for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic breast cancer that cannot be removed by surgery. This includes triple-negative breast cancer or hormone receptor-positive, HER2-negative breast cancer.
- You have not had chemotherapy or other treatments for advanced breast cancer within the last 3 weeks.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- Your heart, bone marrow, liver, and kidney function meet specific lab test values.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This Phase 1b/2 trial tests how safe and how well capecitabine combined with niraparib works for people with HER2-negative, hormone-resistant advanced breast cancer. It may help by slowing tumor growth after standard chemotherapy options have been tried.
This trial checks how a blood test that looks for cancer DNA (ctDNA) changes during and after you take capecitabine after early triple-negative breast cancer. It aims to see whether these blood test results can help monitor the chance of the cancer coming back.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.